Strategy

Apr 26, 2016
The liver disease NASH has become a priority for the healthcare industry – and, potentially, a multi-billion-dollar market.
Apr 01, 2016
Peter Young examines the drivers affecting the biotech industry in 2015, and what to expect in 2016.
Mar 28, 2016
Intense regulatory demands, cost pressure, and the need to be ever more efficient has led to an upturn in the use of management consultants in the pharma & biotech sector, writes B.J. Richards.
Mar 24, 2016
Several factors are combining to change the definition of what healthcare truly is, and how it will be delivered and experienced in the next few years.
Mar 11, 2016
Pharmaceutical Executive
Positioning for success in biopharma requires a self-critical analysis of the risk and rewards among four categories of value differentiation. The key question: How do you define yourself against the competition?
Mar 01, 2016
Bruno Villetelle discusses how Japanese companies like Takeda have begun to digitize in order to care for the country's aging population.
Feb 12, 2016
The recent formation of mega supply-chain purchasing groups such as CVS-Cardinal denotes a shift in the balance of power between wholesalers, chains, generics companies and branded pharma.
Feb 05, 2016
Pharm Exec talks to Jane Griffiths, Company Group Chairman, Janssen EMEA, about how the relationship between industry and patients is maturing.
Feb 05, 2016
Pharmaceutical Executive
An advocate of supply chain business system automation offers a six-pronged approach to adapting to a new age of mounting regulation and customer expectations.
Jan 28, 2016
Companies must design local commercial models that enable them to deliver value stories tailored to the specific needs of organized customers and the characteristics of local ecosystems, writes Paul Darling.
native1_300x100
lorem ipsum